3Settimana·

Scandals, investigative chaos, murders - is the healthcare sector the most dangerous industry in the world?

We need to talk about the healthcare sector today. After 2024 had already disappointed many companies in the sector due to the "corona effect" and was labeled a "transition year", I had actually called for a major recovery in 2025. What happened instead is of course clear: a complete bleed-out of the industry.


In fact, the situation in the healthcare sector is so bad that no returns at all have been achieved across the board in the last three years, and that is bad.


I had actually chosen the healthcare sector as a second pillar in my portfolio alongside my tech investments, as I have a great passion for the topic of healthcare and also like to spend a lot of time on it. Actually, I also had the impression that the healthcare sector is rather defensive as the demand for healthcare services is continuously increasing when there is an increasing number of sicker people in the world. I have therefore created a diversified portfolio of companies that have a predominance in the treatment of a specific disease: Heart defects, mucoviscidosis, diabetes - you can probably already guess where this is going.


At the moment I have several companies in my portfolio whose performance really resembles a horror movie: $ILM1 (+1,28%) , $AFX (-1,3%) , $UNH (+1,84%) , $NOVO B (+2,36%)

Plus some resurrected zombies like $TMO (-0,63%) , $ABBV (+1,45%) , $EW (+0,91%) , $MEDP (-2,08%) whose performance could be reactivated through life-sustaining measures.

Only $SYK (-1,28%) and $VRTX (+1,8%) are developing in line with expectations overall.


In summary, 40% pain, 40% okay and only 20% yes


However, the poor performance is not at all related to the selection of companies. Other giants such as $MRK (+2,69%) and even the most solid healthcare company in the world $JNJ (+0,46%) are not performing satisfactorily either. Some people here in the comments always act as if Novo Nordisk and UNH were the worst companies in the world and everything was foreseeable - but that's just not the case. In fact, they are only falling so sharply and getting so much media coverage because they have always been regarded as the absolute gems in contrast to solala companies like $PFE (+2,07%) it really wasn't an everyday occurrence for them to halve overnight.


Overall, the healthcare sector, which has been battered for years, is now also considered undervalued. So we can still hope for a recovery. Nevertheless, it is slowly becoming a huge problem for me if I put 1/4 of my capital into assets that are outperforming the savings book and not compensating for inflation. The opportunity costs in particular are astronomical, as I have been 80% right in the tech sector in recent years and 80% wrong in the healthcare sector. I spend more money with my left hand than I earn with my right.


The saying comes to mind: "The tide lifts all boats" which is actually supposed to protect against overconfidence. But isn't it also true that an ebb tide lowers all boats? Perhaps neither the great hit rate in the tech sector nor the subterranean hit chance in the health sector is dependent on my investment decisions, but simply a static anomaly.


What I also want to address specifically is that I find it incredibly annoying that investing in the healthcare sector is such a drama club. I sometimes wonder whether we're doing business here or filming a telenovela. I mean, the whole thing with $HIMS (+1,35%) is a complete kindergarten. Why is it that in the automotive industry, complete strangers manage to merge or form alliances just like that and in the healthcare industry they can't even manage to sell a few medications for 3 months without it degenerating into a mud fight and a war of the roses? My gosh.


But now it's up to you. I would be particularly interested to know how people who have been on the market for more than 10 years see it. Have health values always been such a rollercoaster ride or is the industry better than its reputation?

attachment
21
15 Commenti

immagine del profilo
3Settimana
Haven't had any "luck" with the sector in 8 years. With $BAYN and $PFE money 🔥
in my Ultimate Homer wanted to outperform the market with "duration runner" US octopus insurer, again nothing 🤣
8
immagine del profilo
3Settimana
@Simpson But octopuses also want to be insured 🐙
2
immagine del profilo
3Settimana
@Soprano It took me a bit 🤣👍
2
@Simpson then we'll see you again tomorrow in sector 7G😊
1
immagine del profilo
3Settimana
Yes, a very simple yes. If you invest in pharma/healthcare, you have to like the pain. You've actually done everything right, you should diversify as widely as possible in the sector. Patents, lawsuits, canceled approval phases, etc. can mean bitter setbacks. Nevertheless, for me it is the most important industry in the world. Without health, everything is nothing. Everyone strives to live as long as possible. And finally, take a look at global population growth over the past 100 years.
2
immagine del profilo
I am quite happy with my position
$CORT and. $GILD I am quite satisfied. And there are still dividends at Gilead.
$KRYS is now starting to pick up.
2
immagine del profilo
@Tenbagger2024 What exactly does $CORT do?
immagine del profilo
@Aktienorang-Utan
specializes in the development of drugs for the treatment of severe metabolic, cancer and psychiatric diseases. The company focuses on Cushing's syndrome, a hormonal disorder caused by prolonged exposure of body tissue to high concentrations of the hormone cortisol. The market capitalization of the share is currently USD 6.2 billion.

https://aktienmagazin.de/blog/aktienanalysen/trotz-eines-take-profits-kommt-es-zur-konsolidierung-im-musterdepot-mit-diesen-vier-aktien-geht-es-weiter-138083.html
immagine del profilo
@Tenbagger2024 interesting, many thanks for that 😊🤝
1
immagine del profilo
In a nutshell. Thank you.
1
immagine del profilo
I like to invest in the medical technology sector in particular, as these are stable companies in the long term. One of my favorite stocks is Abbott, for example, I have the packages in my hands every day, regardless of whether it's the financial crisis or corona, the stuff is needed and the long-term chart confirms that. The medium-term performance of the sector is not great, but I'm not worried about it in the long term. That's just the way the stock market is and there are always times when everyone goes in a certain direction and some sectors are out for a while. I have $JNJ $ABT $SYK $DHR $UNH $ISRG $COLO B $EW $MTD and $BAYN. Only Stryker and Intuitive Surgical are doing really well, the rest are underperforming. I'm a bit annoyed by Unitedhealth, I wasn't really in the mood for that kind of scam crap, it was actually meant to be a stable stock for the portfolio 😂 but well, the weighting in my portfolio is only slightly higher than in the MSCI World, I can cope with that and my little savings plan is still running. And with shares like $JNJ, which is one of only 3 companies with a AAA rating and which I will probably have forever, I'm actually fine with the share price going sideways for a while while I build up my position with a savings plan, as I get more shares for my money. The share has always had longer sideways phases.
1
immagine del profilo
3Settimana
@Paketknecht Very nice comment
immagine del profilo
Very true words and thoughts
Well, I bought Abbvie at 105 and made a good profit at today's price. This profit covers my losses on Bristol Meyer and Novo. However, I got into Novo shortly before the crash. I don't have any other healthcare stocks. I had also added this sector to my portfolio as an anchor of stability. You have to know that pharmaceutical stocks are very cyclical. Usually they earn their money by launching innovative drugs on the market, which usually only applies to a limited number of drugs. They then earn very well with these drugs until the patent expires. The trick is then to develop suitable follow-up drugs. But that doesn't always work. Patience is required. At the moment, this exchange is somewhat sluggish. What's more, Donald wants lower drug prices. This will also have an impact on earnings. I'm holding the positions and pocketing the dividend. Next year, I'll take another look to see whether restructuring is necessary. A lot has been reported about Novo, and here too I will wait and see and not realize my loss. I have an ambivalent relationship with health insurance companies like United Health. When does a health insurance company make money? When expenses are lower than income. So you have to "control" expenses if you want to increase income and dividends. Does such a company
then cover all the necessary contractual costs? Or do you get sued and pay nothing or less? That may be OK for Warren Buffet, but not for me. To summarize, my opinion is: hold at the moment and wait for the development/quarterly reports for further commitment.
Partecipa alla conversazione